TY  - JOUR

T1  - A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).

JO  - Journal of Clinical Oncology

PY  - 2021/02/20

AU  - Powles T

AU  - Meeks JJ

AU  - Galsky MD

AU  - Van Der Heijden MS

AU  - Nishiyama H

AU  - Al-Ahmadie HA

AU  - Goluboff ET

AU  - Hois S

AU  - Donegan SE

AU  - Williams V

AU  - Xiao F et al

ED  - 

DO  - DOI: 10.1200/jco.2021.39.6_suppl.tps505

PB  - American Society of Clinical Oncology (ASCO)

VL  - 39

IS  - 6_suppl

SP  - TPS505

EP  - TPS505

Y2  - 2024/12/22

ER  -